STUDIES OF THE NATURAL HISTORY AND TREATMENT OF CHRONIC HEPATITIS C

有充分证据的慢性丙型肝炎患者 正在进行评估以确定地球的长期自然历史 这种常见的慢性肝病。一群这样的人 患者可以评估实验疗法。上一首 研究表明，α-干扰素治疗短期有效。 对大约50%的患者有有益效果。这 在停止后，响应保持在大约10%-15% 干扰素。利巴韦林的随机、安慰剂对照试验 表明这种核苷类似物的1年疗程是 与血清转氨酶显著改善有关 血清不变时肝小叶坏死的活动性 丙型肝炎病毒核糖核酸水平。利巴韦林持续治疗长达2年 证明了长期抑制疗法在这方面的实用性 疾病。利巴韦林与利巴韦林联合应用的对照试验 干扰素已经启动。没有反应的患者将被 继续接受利巴韦林单独或安慰剂治疗以评估 利巴韦林长期治疗能否改善慢性阻塞性肺疾病 丙型肝炎患者对所有治疗方法都耐药。

Patients with well-documented chronic hepatitis C are being evaluated to determine the long-term natural history of this common form of chronic liver disease. A cohort of such patients are available to evaluate experimental therapies. Previous studies have shown that alpha interferon therapy has a short-term beneficial effect in approximately 50 per cent of patients. This response is sustained in approximately 10-15 per cent after stopping interferon. A randomized, placebo-controlled trial of ribavirin showed that a 1 year course of this nucleoside analogue is associated with significant improvement in serum aminotransferase activities and in hepatic lobular necrosis despite unchanged serum levels of HCV RNA. Continous ribavirin therapy for up to 2 years demonstrated the practicality of long term supressive therapy in this disease. A controlled trial of the combination of ribavirin and interferon has been initiated. Patients who do not respond will be continued on therapy with ribavirin alone or placebo to assess whether long term therapy with ribavirin can improve chronic hepatitis C in patients resistant to all therapies.